Horie Tetsuhiro, Kuwano Ayane, Sakamoto Takuya, Nakamura Yuka, Yamaguchi Kayoko, Tanida Ikuhiro, Osawa Satoshi, Yasumoto Kazuo, Ishigaki Yasuhito
Medical Research Institute, Kanazawa Medical University, Kahoku, Ishikawa, 920-0293, Japan.
Department of Pharmacy, Kanazawa Medical University Hospital, Kahoku, Ishikawa, 920-0293, Japan.
Discov Oncol. 2025 Apr 26;16(1):620. doi: 10.1007/s12672-025-02394-6.
Lung cancer is the leading cause of cancer-related mortality worldwide; however, despite the development and clinical application of various drugs, the prognosis remains poor. One reason for this is the high rate of recurrence and metastasis. The cancer stem cell (CSC) theory has been proposed to explain their root cause, and removal of CSCs is necessary to cure cancer completely; however, detailed profiles of lung CSCs have not been clarified. Here, we used single-cell RNA sequencing (scRNA-seq) data to identify novel markers for lung CSCs and validated their expression and function in vitro.
A549-derived tumorspheres were used as a model for lung CSCs. To identify genes upregulated in CSC-like cells, we reanalyzed two publicly available scRNA-seq datasets from human lung cancer tissues. Additionally, trajectory analysis was performed to examine changes in candidate gene expression during CSC differentiation. The role of these candidate genes in CSC regulation was further investigated through functional assays.
Tumorspheres exhibited increased expression of well-established CSC markers. scRNA-seq analysis suggested that SIGMAR1 expression was significantly upregulated in CSC-like cells and decreased with differentiation. Furthermore, siRNA-mediated SIGMAR1 knockdown suppressed tumorsphere self-renewal capacity and reduced CSC marker expression.
We propose that SIGMAR1 serves as a potential functional marker of CSCs and plays a crucial role in regulating self-renewal capacity. Targeting SIGMAR1 may provide a novel therapeutic strategy for preventing metastasis and recurrence-major clinical challenges in lung cancer treatment. Future studies should investigate the underlying mechanisms by which SIGMAR1 modulates CSC properties.
肺癌是全球癌症相关死亡的主要原因;然而,尽管各种药物不断发展并应用于临床,其预后仍然很差。原因之一是复发和转移率很高。癌症干细胞(CSC)理论被提出来解释其根本原因,并且去除CSC对于完全治愈癌症是必要的;然而,肺CSC的详细特征尚未阐明。在此,我们使用单细胞RNA测序(scRNA-seq)数据来鉴定肺CSC的新型标志物,并在体外验证它们的表达和功能。
将A549来源的肿瘤球用作肺CSC的模型。为了鉴定在CSC样细胞中上调的基因,我们重新分析了来自人肺癌组织的两个公开可用的scRNA-seq数据集。此外,进行轨迹分析以检查CSC分化过程中候选基因表达的变化。通过功能试验进一步研究这些候选基因在CSC调节中的作用。
肿瘤球表现出已确立的CSC标志物表达增加。scRNA-seq分析表明,SIGMAR1在CSC样细胞中的表达显著上调,并随着分化而降低。此外,siRNA介导的SIGMAR1敲低抑制了肿瘤球的自我更新能力,并降低了CSC标志物的表达。
我们提出SIGMAR1作为CSC的潜在功能标志物,并在调节自我更新能力中起关键作用。靶向SIGMAR1可能为预防转移和复发——肺癌治疗中的主要临床挑战——提供一种新的治疗策略。未来的研究应调查SIGMAR1调节CSC特性的潜在机制。